InstalabInstalabLoading...
Instalab ResearchAcross thousands of patients in 3- to 12-month studies, the most commonly reported side effects at the standard 50 mg dose are:
These were generally rated mild to moderate. Dizziness, constipation, and tachycardia (a faster-than-normal heartbeat) also appeared in the data, but at rates similar to what was seen in both placebo groups and people taking antimuscarinics. In other words, those effects weren't clearly caused by mirabegron itself.
Urinary retention, a concern with any bladder drug, was rare: less than 1% across trials.
This is where mirabegron deserves a closer look. At the 50 mg dose, studies show an average systolic blood pressure increase of roughly 0–1 mmHg, along with a slight bump in pulse rate. For most people, that's clinically insignificant. Hypertension was reported in about 4% of mirabegron users, but that rate was similar to placebo.
The picture changes at higher, experimental doses. At 100–200 mg (used in obesity research, not standard OAB treatment), the risk of tachycardia and blood pressure elevation climbs meaningfully. The standard 50 mg OAB dose shows only minor cardiovascular changes by comparison.
If you have severe uncontrolled hypertension or heart rhythm problems, this small signal matters more for you than for the average patient. Monitoring and a conversation with your clinician are warranted.
The research makes this comparison straightforward. Here's what the trials show at standard doses:
| Side Effect | Mirabegron 50 mg | Antimuscarinics (tolterodine, solifenacin, etc.) |
|---|---|---|
| Dry mouth | ~2–3%, similar to placebo | 6–9%+, significantly higher |
| Constipation | ~2%, low | Higher, especially in older adults |
| Hypertension | ~4%, similar to placebo | Similar rates overall |
The standout difference is dry mouth and constipation. These are the side effects that most commonly drive people to quit antimuscarinic drugs, and mirabegron largely sidesteps both. On blood pressure, neither drug class comes out clearly better or worse.
Atrial fibrillation and other arrhythmias are very rare with mirabegron. In one 12-month combination trial, a single case of atrial fibrillation was noted as possibly related to treatment. That's the kind of finding that shows up in a safety database but shouldn't drive most decisions.
The research doesn't address long-term effects beyond 12 months in detail, so there's an honest gap there. What the 3- to 12-month data across thousands of patients does show is a consistently favorable safety profile.
Mirabegron makes the most practical sense if you've tried an antimuscarinic and quit because of dry mouth, constipation, or other classic side effects. The research clearly supports that mirabegron causes far less of both.
It's a reasonable first-line choice, too, given its overall tolerability. But it's not entirely side-effect-free, and a few groups should be more cautious:
For most people, the practical reality is this: mirabegron's side effect profile is mild, the dry mouth advantage over older drugs is real and consistent, and the blood pressure effect at standard doses is small enough that periodic monitoring handles it.